# US 2015/0147290 A1 · Use of g-csf dimer in the treatment of neutropenia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147290 A1
- Document ID: US20150147290A1
- Status: Published application
- Kind: A1
- Application number: 14/526,382
- Filed: 2014-10-28
- Published: 2015-05-28
- Earliest claimed: 2010-08-31
- Assignees: Generon (Shanghai) Corporation Ltd.
- Applicants: Generon (Shanghai) Corporation, LTD.
- Inventors: Xiaoqiang YAN; Zhihua Huang; Hongzhou Yang; Bill N. Sun; Yuliang Huang
- Web page: https://patentgrep.com/patent/US20150147290A1

## CPC

- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 37/04: Immunostimulants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to a use of G-CSF dimer in the treatment of neutropenia. In particular, the recombinant human G-CSF of the present invention can enhance the differentiation and development of neutrophils in animal, and thus effectively reduce the severity of the severe neutropenia and shorten the time of severe neutropenia for the post-chemotherapy cancer patients. Serum half-life of G-CSF dimer of this invention is prolonged and the biological activity thereof is increased, providing a better effect in the treatment of neutropenia.

## Claims

### Claim 1

A method of treating neutropenia in an individual comprising administering to the individual a human granulocyte colony-stimulating factor (G-CSF) dimer.

### Claim 2 (depends on 1)

The method of claim 1, wherein said neutropenia comprises a condition in which said neutropenia is induced by chemotherapy and/or radiotherapy.

### Claim 3 (depends on 1)

The method of claim 1, wherein said human G-CSF dimer is shown as formula (I):
M1-L-M2 (I)
wherein
M1 is a first human G-CSF monomer;
M2 is a second human G-CSF monomer; and
L is a linker connecting said first monomer and said second monomer and disposed therebetween,
said G-CSF dimer retains the biological activity of a G-CSF monomer and has a serum half-life of at least twice of the half-life of either said first or said second monomer.

### Claim 4 (depends on 3)

The method of claim 3, wherein said linker L is selected from the group consisting of:
i) a short peptide comprising 3 to 50 amino acids; and
ii) a polypeptide of formula (II):
—Z—Y—Z— (II)
wherein
Y is a carrier protein;
Z is null, or a short peptide(s) comprising 1 to 30 amino acids;
“—” is a chemical bond or a covalent bond.

### Claim 5 (depends on 3)

The method of claim 3, wherein said first monomer and said second monomer are of the same entity.

### Claim 6 (depends on 3)

The method of claim 3, wherein said biological activity comprises:
(a) acting on neutrophil precursor cells and myeloid stem cells to drive the differentiation, development, and maturation of neutrophils; and
(b) activating mature neutrophils to participate in immune response.

### Claim 7 (depends on 4)

The method of claim 4, wherein said carrier protein is albumin or Fc fragment of human IgG.

### Claim 8 (depends on 4)

The method of claim 4, wherein said “—” is a peptide bond.

### Claim 9 (depends on 4)

The method of claim 4, wherein said G-CSF dimer is formed by monomers in which said monomer comprises an amino acid sequence selected from a group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein said G-CSF dimer is formed by monomers comprising G-CSF and Fc.

### Claim 12 (depends on 11)

The method of claim 11, wherein the two monomers are connected by disulfide bonds.

### Claim 13 (depends on 1)

The method of claim 1, wherein the neutropenia is severe neutropenia.

### Claim 14 (depends on 11)

The method of claim 11, wherein the neutropenia is severe neutropenia.

### Claim 15 (depends on 12)

The method of claim 12, wherein the neutropenia is severe neutropenia.

### Claim 16

A method of activating neutrophil precursor cells and myeloid stem cells in an individual comprising administering to the individual a human granulocyte colony-stimulating factor (G-CSF) dimer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the individual has severe neutropenia.

### Claim 18 (depends on 16)

The method of claim 16, wherein said G-CSF dimer is formed by monomers comprising G-CSF and Fc.

### Claim 19

A method of activating mature neutrophils in an individual comprising administering to the individual a human granulocyte colony-stimulating factor (G-CSF) dimer.

### Claim 20 (depends on 17)

The method of claim 17, wherein the individual has severe neutropenia.

### Claim 21 (depends on 17)

The method of claim 17, wherein said G-CSF dimer is formed by monomers comprising G-CSF and Fc.
